Commercial Space Company Risk / Opportunity Ranking

Thesis: Muon Space has some long-horizon optionality because the reviewed sources context places it in satellite constellations and atmospheric/ocean/land measurement, suggesting a real operating footprint in an attractive segment.

Why now: The most recent dated context is a May 22, 2026 job posting indicating contracting and legal operations needs, which may imply organizational buildout but is weak evidence for a major catalyst.

Caveats: The reviewed sources contain no direct positive or negative company-specific events. The May 22, 2026 job posting is operational context, not proof of revenue or contracts. Citation

Thesis: Reviewed evidence context identifies NordSpace as one of three Canadian rocket startups awarded government funding, which is a constructive signal for a long-horizon launch-company buildout, but there is no available in-window evidence to assess amount, timing, milestones, or commercialization follow-through.

Why now: The only directional clue is the membership-support article reference: but the reviewed sources includes no, no summary, and no available post-recent evidence window evidence, so timing and durability are uncertain.

Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources provide no or article summary. Opportunity case relies on generic funding support mention without current milestone evidence.

Thesis: Orbit Fab appears strategically interesting in on-orbit refueling and space logistics. The company website summary describes 'In-Space Fuel Delivery,' RAFTI refueling interfaces, and 'Hydrazine Delivery in GEO for 100kg. Available in 2025,' which would matter over a 1 year+ horizon if still current, but that article is dated December 24, 2022 and outside the 90-day recent evidence window, so it is only weak historical context. Within retained evidence, an undated external list says Orbit Fab is 'operating' in in-orbit servicing, which supports relevance but not a strong near-current thesis.

Why now: Why now is only moderate because retained evidence after filtering consists of undated context from Space Index, not a dated current catalyst; the older company-site article from December 24, 2022 may indicate strategic readiness, but recency is weak

Caveats: Retained evidence is weak context and supporting article context, not direct event/fact evidence. The more detailed article is dated December 24, 2022 and was dropped by the 90-day recent evidence window; it should not be treated as current proof. The undated Space Index row is relevance context only and not recency proof.

Thesis: OrbitAID appears positioned in on-orbit refueling, docking, repair, inspection, and life-extension services, which could be strategically attractive over a 1 year+ horizon if execution follows, but the reviewed sources only provides undated article-level company context rather than dated wins, funding, customers, or milestones.

Why now: Why now is weak because the surviving evidence is undated company-context material rather than a fresh milestone. Recency-sensitive claims are uncertain

Caveats: Evidence kept after recent evidence window is undated and marked context, not recency proof. No direct positive event, contract, financing, or customer traction is available. Same-article repeated rows are not independent confirmation.

Thesis: Among this screen, Orbital has one of the clearer positive reviewed sources rationales: it is described as a private space startup with funding and a planned LEO satellite for orbital data centers, which suggests longer-horizon strategic buildout potential if execution continues, and, no provided in reviewed sources).

Why now: The only reason to rank it slightly above peers is the reviewed sources' description of funding plus a planned LEO satellite, which is at least directionally aligned with a 1 year+ horizon. But there is no retained dated evidence to verify recency, sequencing, or milestone timing.

Caveats: No are provided for the cited support articles in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. The positive view comes from phase2 rationale text rather than available direct event/facts.

Thesis: Orbital Recovery Crew presents a speculative long-horizon opportunity because recent website-level context claims it provides end-to-end retrieval, repositioning, and deorbit services across LEO, MEO, and GEO and is 'Licensed. Insured. Operational since 2011,' which, if accurate, implies operational positioning in on-orbit servicing and debris removal.

Why now: The only retained evidence is a page with May 21, 2026, within the 90-day window, indicating recent discoverable claims of operations and service scope, but not a third-party validated catalyst.

Caveats: Evidence is company-site article context, not independent confirmation. No direct positive or negative dated events are available. Same-article repeated rows are not independent confirmation.

Thesis: Planet Labs is clearly relevant as a satellite constellation and geospatial data company, but the reviewed sources only provides generic article-level business description rather than a dated catalyst or company-specific contract milestone.

Why now: Why-now is weak: the only in-window evidence is an April 5, 2026 startup-listing article describing Planet as operating its own satellite constellation and geospatial analytics platform, which is durable context but not a clear catalyst.

Caveats: Evidence is only supporting article context, not direct company event or fact evidence with strong materiality. No direct positive or negative dated events are available. This is a low-conviction watchlist name in these reviewed sources.

Thesis: Reviewed evidence rationale identifies Reaction Dynamics as one of three Canadian rocket startups awarded government funding. Government support can be a meaningful de-risking signal for a 1 year+ development runway if still current.

Why now: The support is tied to article: in the membership rationale, which suggests a relatively recent funding-related development, but the active evidence set still contains zero available rows after recent evidence filtering.

Caveats: Government funding mention is promising but unquantified in the active evidence set. No chronology-confirmed operational updates are available.

Thesis: Among this screen, Sierra Nevada Corporation has one of the more plausible long-horizon opportunity setups because the reviewed sources rationale says SNC has a small satellite constellation, Vindler 2.0, and on-orbit RF data transmission activity, which could indicate real space-communications or constellation relevance if validated.

Why now: If the referenced constellation and on-orbit transmission activity are current, they could matter over a 1 year+ horizon; however, the reviewed sources provide no available after-recent evidence window evidence to confirm recency or milestone sequence.

Caveats: Phase-2 rationale references: and: but no or article summaries are included. The reviewed sources explicitly warns that the evidence mixes SNC and Sierra Space-adjacent themes. Coverage debug shows zero evidence after recent evidence window, so direct validation is unavailable.

Thesis: An undated supporting article context item says Astroscale and SKY Perfect JSAT formed a strategic partnership on on-orbit servicing and that the partnership includes an investment by SKY Perfect JSAT, which could support strategic optionality in adjacent space services if current

Why now: This is one of the only companies in the screen with any current evidence surviving the recent evidence window, but it is undated supporting context, so why-now confidence is still limited

Caveats: Evidence is undated and supporting article context only. Same article appears in multiple weak-context rows and is not independent confirmation. No direct positive event/fact beyond supporting context.

Thesis: Spacecoin may have speculative upside over a 1 year+ horizon because the reviewed sources describes it as a private blockchain startup using satellite-based transactions and aiming at a decentralized satellite network, which could represent an emerging infrastructure concept if execution materializes.

Why now: If the network concept is advancing, that could be relevant over a long horizon, but the reviewed sources offers no available recency-validated milestone evidence after recent evidence window.

Caveats: Phase-2 rationale references and, but no or summaries are included. Business-model adjacency to satellite communications is not the same as proven operating traction. Coverage debug shows zero evidence after recent evidence window.

Thesis: Spaceflux has a plausible long-horizon opportunity setup because the reviewed sources' membership rationale says it received a £100K follow-on investment through a UK space funding program and notes relevance to debris tracking. That can support an SDA-adjacent thesis, but the reviewed sources lack direct positive evidence and gives no or dated article detail to confirm magnitude or timing (: not provided in reviewed sources).

Why now: A follow-on investment could matter over 1 year+ if it extends development in debris tracking, but there is no available dated evidence within the recent evidence window and no direct article summary/ in the reviewed sources.

Caveats: Only article-level rationale is available. Funding size may be modest, but reviewed sources does not provide enough context to judge materiality precisely. No representative article or quote available.

Thesis: The reviewed sources membership rationale describes SWISSto12 as delivering HummingSat GEO telecom platforms and NEASTAR-1 direct-to-device media broadcasting capability, which, if current, suggests exposure to durable satellite communications platform programs over a 1 year+ horizon.

Why now: There is no dated evidence retained after recent evidence window for SWISSto12. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window, so the timing case is not established from these reviewed sources.

Caveats: Assessment relies only on the reviewed sources' membership rationale, not direct quoted event/fact evidence with support. No representative articles are included despite article IDs being referenced in the rationale. Potential opportunity could be meaningful, but evidentiary support inside these reviewed sources is too thin for a stronger score.

Thesis: TM2SPACE may have opportunity from reported selection for IN-SPACe funding under the Technology Adoption Fund for AI-powered star tracker systems, but the reviewed sources does not include the underlying article summaries or evidence in the served evidence section.

Why now: The membership rationale references selection for IN-SPACe funding and AI-powered star tracker work using article IDs, and: but no article summaries, or direct evidence are available in these reviewed sources after recent evidence window, so recency and materiality cannot be independently verified from the evidence body.

Caveats: No representative articles, or available evidence available to cite directly beyond membership rationale. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window. Scoring is conservative because reviewed sources support is incomplete in the visible evidence section.

Thesis: Reviewed evidence membership rationale says True Anomaly was included among 14 vendors selected by the U.S. Space Force for space monitoring satellites under the Andromeda program. If current, that implies meaningful government-program relevance over a 1-year-plus horizon, but the reviewed sources lack citeable direct evidence or.

Why now: Government program selection could matter over 1 year+, but the reviewed sources does not provide surviving evidence with timing details after recent evidence window.

Caveats: No -bearing direct evidence row is available for the referenced Andromeda selection article. Selection does not prove revenue realization or contract scale.

Thesis: Turion Space may have an attractive defense and space-monitoring positioning based on the membership rationale mentioning fundraising, U.S. government contracts, STRATFI launches, and Andromeda selection, but the reviewed sources includes no within the recent evidence window evidence or article summaries to support a high-conviction opportunity ranking.

Why now: No within the recent evidence window evidence was available in these reviewed sources, so the timing case is weak despite the strategic framing in the membership rationale.

Caveats: Membership rationale references article IDs and, but no article content is provided here for citation. Evidence recent evidence review shows 0 kept rows. Scores remain conservative because the reviewed sources lack usable direct evidence.

Thesis: Reviewed evidence rationale says Vast raised $500M and is building Haven commercial space stations and related habitats, which would be material long-duration opportunity if current, but these reviewed sources contain no within the recent evidence window direct evidence or representative article summaries to support a stronger score.

Why now: Why-now is unproven from these reviewed sources because no dated evidence survived the 90-day recent evidence window despite 11 articles considered.

Caveats: Phase2 membership rationale references and, but no summaries or evidence are available for citation. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Scores remain near low baseline due to absence of directly citable local evidence.

Thesis: Reviewed evidence context says Voyager Technologies is developing the Starlab space station, which is strategically meaningful for a 1 year+ horizon if execution continues, but no direct in-window evidence is available to confirm current milestones, financing, contract conversion, or timetable.

Why now: No current catalyst is evidenced in the reviewed sources. Although membership support references article IDs and, the reviewed sources show 0 article IDs after recent evidence window and 0 evidence after recent evidence window, so business-state recency cannot be established.

Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article IDs and, but the reviewed sources provide no or article summaries for citation.

Thesis: Reviewed evidence context indicates WISeKey, via WISeSat, is tied to a planned QSOC 100-satellite constellation with post-quantum satellite launches. If executed, that could matter over a 1 year+ horizon, but the reviewed sources provide no current in-window evidence confirming launch cadence, financing, customer uptake, or operational progress.

Why now: There is no documented near-term catalyst in the available evidence. Membership support cites article IDs and, but the reviewed sources reports 0 article IDs after recent evidence window and 0 evidence after recent evidence window.

Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article IDs and, but the reviewed sources does not include or article summaries for citation. Risk is inferred from lack of current execution proof, not from a confirmed adverse event.

Thesis: Xona has potential strategic opportunity because the reviewed sources describes Pulsar as a low-Earth-orbit positioning, navigation, and timing infrastructure using 258 small satellites, implying an ambitious constellation and differentiated service if executed.

Why now: Why now is weak: the only surviving evidence is undated, so recency-sensitive claims are uncertain

Caveats: Evidence is undated and should not be treated as recency proof. No direct positive event or traction evidence is available. Opportunity case is strategic but low-conviction.

Thesis: Article-level context also highlights structural Earth observation monetization difficulty and long procurement cycles, creating real commercialization risk even after the raise.

Why now: Xoople closed a $130 million Series B on April 6, 2026/07 and articles say the capital is for building out its constellation; for a 1 year+ horizon, that financing can enable product and deployment progress, but the same dated coverage warns the market has historically been hard to monetize.

Caveats: Positive support is mostly supporting article context rather than positive evidence. Commercialization warning is article context, not a company-specific deterioration event. No direct customer, backlog, or launch milestone evidence is available.

Thesis: There is no direct adverse evidence in the reviewed sources, so risk is moderate-low and mostly reflects inability to verify current contract progression, funding conversion, or execution status from available evidence (: unavailable in reviewed sources).

Why now: Why now is weak because the reviewed sources' recent evidence review and coverage data show zero available evidence after recent evidence window despite the membership rationale referencing a material contract.

Caveats: No current evidence is provided for Contract claim appears only in membership rationale, not in available direct evidence fields. No recency-confirmed follow-through evidence is available.

Thesis: Aavuus remains early-stage, and the evidence is supporting article context rather than direct positive events; the same article describes only pre-seed funding, which implies execution and scaling risk over a 1 year+ horizon.

Why now: The opportunity is timely because the retained article is dated June 9, 2026 and describes a current financing and product build phase rather than stale background context. That said, recency comes from source date/article date, and evidence grounding is still article-level rather than direct fact/events., June 9, 2026

Caveats: Evidence is weak context and supporting article context, not direct structured positive event evidence. No explicit customer, contract, revenue, or regulatory milestone is cited. Same article appears in multiple rows and is not independent confirmation.

Thesis: Risk is modestly elevated because the reviewed sources' membership rationale describes it as a startup that emerged from stealth and raised only a $4M pre-seed, implying early-stage execution and financing risk, but this is not backed by available dated evidence in the ranking payload.

Why now: There is no available dated evidence in the reviewed sources after recent evidence filtering, so recency-based ranking support is weak.

Caveats: No representative articles or evidence are available after recent evidence filtering for ranking support. The phase2 membership rationale mentions a $4M pre-seed and Star Reacher Network, but the cited supporting articles are not provided with usable article summaries or evidence in these reviewed sources.

Thesis: No direct negative evidence is available; the main risk in this ranking is evidence insufficiency rather than a documented adverse development.

Why now: Why-now support is weak because coverage data shows no evidence after recent evidence window, so the cited lunar contract context cannot be refreshed from available evidence.

Caveats: Phase2 rationale cites, and: but no representative article or evidence are available for direct citation. Coverage data reports articles after recent evidence window = 0 and evidence after recent evidence window = 0. Private-company watch item rather than high-conviction ranked candidate.

Thesis: No direct negative evidence is available. Remaining risk comes from the lack of post-recent evidence window evidence proving contract conversion, revenue realization, or mission execution scale.

Why now: Why now is relatively constructive because a named partnership for on-orbit services can matter over a long strategic horizon, but exact timing and materiality cannot be validated from the reviewed sources because only membership rationale is visible.

Caveats: Membership rationale references article ID: but the reviewed sources provide no or article summary. Relation counts are present in support metadata, but relations are context-only unless separately policy-gated. No direct positive or negative evidence arrays are populated.

Thesis: No material negative evidence is present; risk is mainly execution and evidence-gap risk because current launch timing, deployment success, and monetization are not substantiated by the available reviewed sources evidence (: unavailable in reviewed sources).

Why now: Why now is weak because the reviewed sources references a potentially important constellation expansion but provides no post-recent evidence window available evidence to confirm status or timing.

Caveats: No current evidence is provided for No direct evidence remained after the recent evidence filter. Recency of constellation expansion cannot be validated from reviewed sources fields.

Thesis: Risk is modestly elevated because the membership rationale describes IPO and reusable rocket development ambitions, both of which imply capital intensity and execution risk, but there is no available adverse evidence.

Why now: There is no usable dated evidence available after recent evidence filtering, so the reviewed sources does not provide a clear timing catalyst.

Caveats: The membership rationale references an IPO and Lijian-1 launch activity, but those source articles are not included with ranking-usable details in these reviewed sources.

Thesis: The positive financing evidence is stale relative to the reviewed sources' 90-day recent evidence window. The article is dated February 14, 2026, which the reviewed sources say was dropped by the recent evidence filter, so there is no current-window evidence confirming whether financing momentum, backlog conversion, or product adoption continued

Why now: There is no fresh catalyst inside the 90-day evidence window. The visible article was published on February 14, 2026 and is outside the cutoff date of March 29, 2026, so it is useful as background but weak for recency-sensitive ranking

Caveats: The visible positive article is outside the 90-day recent evidence window cutoff and was dropped from reviewed evidence. External supporting source context is allowed as evidence context but is not merged into primary data source.

Thesis: Risks center on execution and evidence quality rather than explicit adverse news. The financing article carries internal chronology ambiguity because the page was published in 2026 but references a January 19, 2023 financing round, and the overall reviewed sources lack direct negative events, contract-performance data, or milestone completion proof.

Why now: Why now is supported by recent dated context: on June 24, 2026, SpaceNews reported ClearSpace signed an MOU with Shield Space to develop sovereign space defense capabilities for the UK and allies, indicating adjacent market expansion. On May 19, 2026, the company site said it had finalized a EUR 26.7 million Series A and was ramping operations ahead of ClearSpace-1 scheduled to launch in 2026. These dated items fit a 1 year+ horizon because they point to ongoing commercialization and mission preparation.

Caveats: Most evidence is supporting article context, not direct positive events. The financing article published on May 19, 2026 references January 19, 2023 for the Series A round, so funding recency versus page recency should not be conflated.

Thesis: No direct negative evidence is present. Risk remains moderate because the evidence base is only one cited article with no available direct events, leaving uncertainty on commercialization, timeline, and conversion from demonstration activity to durable revenue.

Why now: Why now is the partnership/demo claim referenced in article ID, but the reviewed sources includes neither nor explicit article timing beyond the article ID prefix, limiting recency precision.

Caveats: Opportunity rests on membership rationale rather than fully available direct evidence. Referenced article ID has no in the reviewed sources. Demo activity is not the same as proven commercial traction.

Thesis: Risk is non-trivial because the thesis depends on execution of a global rollout in a capital-intensive reusable space transportation market, but the reviewed sources does not show direct adverse events. Risk is therefore moderate rather than high.

Why now: The key catalyst is recent and explicit: on June 16, 2026 the company announced the Series B close and said the proceeds will finance global rollout and scaling of commercial and operational teams in the US and Europe.

Caveats: Evidence comes from a company-published article, so it is not fully independent. No direct structured positive event row is provided beyond supporting article context.

Thesis: Because the reviewed sources frames the company around surveillance/spy satellite activity rather than commercial traction, and provides no direct positive operating evidence, the name screens as a limited-visibility watchlist with modest evidence-based risk.

Why now: Why now is weak because there are no available post-recent evidence window evidence, no article summaries, and no clear near- or long-horizon catalyst beyond generic association with a surveillance satellite.

Caveats: Membership rationale cites article IDs and, but the reviewed sources provide no. Company is private and evidence coverage inside the recent evidence window is empty.

Thesis: Execution and financing risk remain material because the reviewed sources contain no kept direct evidence on follow-on funding, customer adoption, revenue conversion, or post-demo performance; technology demonstration does not by itself prove scale-up.

Why now: The membership support references articles, and, implying a narrative of funding plus orbital demonstration, but active evidence remains empty after recent evidence filtering, limiting recency confidence.

Caveats: In-orbit demo claim appears only in reviewed sources rationale, not available direct evidence. No evidence confirms whether the prior seed round falls within the current decision horizon relevance. No direct adverse evidence is present, but that is not proof of low fundamental risk.

Thesis: Risk is mostly commercialization uncertainty. The reviewed sources does not provide direct negative evidence, but it also lacks direct available proof of revenue, customer conversion, or broader market adoption.

Why now: Why now is the reviewed sources' claim that the company addresses a key EO data-processing bottleneck and has space-agency support, referenced to article ID: though no or timestamp detail was provided.

Caveats: Claims come from membership rationale rather than direct evidence. Referenced article ID: lacks a reviewed sources. Support from agencies and target users is weaker than demonstrated contracted revenue.

Thesis: The reviewed sources' clearest adverse context is that EON Space Labs was identified as one of the Indian private space companies affected by a PSLV failure, which could create execution, schedule, or financing ripple effects over a 1 year+ horizon, though the underlying article detail is not surfaced in the scoring evidence fields.

Why now: Why now is stronger than for most names here because the phase2 rationale specifically ties EON Space Labs to a PSLV failure context via article: implying a concrete event rather than generic company context. However, conviction remains low because the reviewed sources omits the underlying event summary and dates in the evidence exposed here.

Caveats: The adverse signal appears only in phase2 rationale, not in direct negative evidence. No article summary, quote, or timing detail is provided in the scoring fields. Impact magnitude on EON specifically cannot be quantified from these reviewed sources alone.

Thesis: Risk remains moderate because the reviewed sources offers only one supporting article context and no direct positive event row beyond that summary, leaving unclear whether the satellite is generating revenue, delivering performance, or leading to follow-on orders.

Why now: Why now is the dated first-satellite launch article from May 5, 2026, which is recent within the 90-day recent evidence window and relevant to a long-horizon de-risking story, though still early-stage.

Caveats: Evidence is supporting article context only, not a stronger structured positive event row. Single-article universe limits corroboration. No financing, customer, revenue, or performance follow-through evidence is provided.

Thesis: Execution and commercialization risk remain meaningful because the retained evidence is still mainly company-provided article context and a technology demonstration milestone, not third-party validated contract wins, revenue conversion, or mission success; an undated directory listing that GITAI is 'operating' is weaker context and not recency proof.

Why now: The key catalyst is recent and inside recent evidence window: on June 16, 2026, GITAI announced completion of the S3 flight model for an on-orbit servicing demonstration mission, which is directly relevant to a 1 year+ horizon because it may precede launch, demonstration, and downstream defense/commercial adoption over the next year.

Caveats: Primary evidence is from the company itself. No retained independent customer, contract, or revenue evidence is provided. The spaceindex.io entry is undated and should not be treated as recency proof.

Thesis: The same reviewed sources rationale says Goonhilly is being acquired by Intuitive Machines, which can create integration, ownership, and business-state uncertainty over a 1 year+ horizon. Because no retained dated evidence are available, this risk is only moderately ranked.

Why now: The only 'why now' available is the reviewed sources' statement that Goonhilly is being acquired by Intuitive Machines, cited in phase-2 support, and: but no, timestamps, or retained evidence are provided, so recency and sequence cannot be validated.

Caveats: The reviewed sources rationale states Goonhilly has ground-station/COMSAT revenue and is being acquired by Intuitive Machines, tied to, and: but no or retained evidence are present. Coverage debug still shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Because chronology cannot be verified, transaction-state claims should be treated cautiously.

Thesis: The reviewed sources does not show material adverse company-specific events; main risk is that most support is financing/context evidence rather than audited operating metrics or margins.

Why now: On June 9, 2026 ICEYE disclosed a €450 million primary Series F at valuation above €10 billion, with total round size above €1 billion including secondary, and later June context also referenced a €300 million revolving credit facility and additional sovereign satellite demand; those are recent business-state signals for a 1 year+ horizon.

Caveats: Some support is supporting article context rather than company-specific positive evidence. Several supporting demand/customer references are undated, so recency is uncertain for those claims.